Pfizer Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 26, 2025, 5:48 pm

Competitors of Pfizer Ltd

All Competitor Stocks of Pfizer Ltd

Quarterly Result

Last Updated: August 20, 2025, 5:35 am

Below is a detailed analysis of the quarterly data for Pfizer Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 603.00 Cr.. The value appears strong and on an upward trend. It has increased from 592.00 Cr. (Mar 2025) to 603.00 Cr., marking an increase of 11.00 Cr..
• For Expenses, as of Jun 2025, the value is 393.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 364.00 Cr. (Mar 2025) to 393.00 Cr., marking an increase of 29.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 210.00 Cr.. The value appears to be declining and may need further review. It has decreased from 228.00 Cr. (Mar 2025) to 210.00 Cr., marking a decrease of 18.00 Cr..
• For OPM %, as of Jun 2025, the value is 35.00%. The value appears to be declining and may need further review. It has decreased from 38.00% (Mar 2025) to 35.00%, marking a decrease of 3.00%.
• For Other Income, as of Jun 2025, the value is 67.00 Cr.. The value appears to be declining and may need further review. It has decreased from 217.00 Cr. (Mar 2025) to 67.00 Cr., marking a decrease of 150.00 Cr..
• For Interest, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
• For Depreciation, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 2.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 260.00 Cr.. The value appears to be declining and may need further review. It has decreased from 426.00 Cr. (Mar 2025) to 260.00 Cr., marking a decrease of 166.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Mar 2025) to 26.00%, marking an increase of 4.00%.
• For Net Profit, as of Jun 2025, the value is 192.00 Cr.. The value appears to be declining and may need further review. It has decreased from 331.00 Cr. (Mar 2025) to 192.00 Cr., marking a decrease of 139.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 41.91. The value appears to be declining and may need further review. It has decreased from 72.34 (Mar 2025) to 41.91, marking a decrease of 30.43.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 4:42 am

Growth

Last Updated: September 5, 2025, 12:15 pm

Balance Sheet

Last Updated: June 16, 2025, 11:33 am

Below is a detailed analysis of the balance sheet data for Pfizer Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 46.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 46.00 Cr..
• For Reserves, as of Mar 2025, the value is 4,172.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,550.00 Cr. (Mar 2024) to 4,172.00 Cr., marking an increase of 622.00 Cr..
• For Borrowings, as of Mar 2025, the value is 41.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 40.00 Cr. (Mar 2024) to 41.00 Cr., marking an increase of 1.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 653.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 593.00 Cr. (Mar 2024) to 653.00 Cr., marking an increase of 60.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 4,911.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,229.00 Cr. (Mar 2024) to 4,911.00 Cr., marking an increase of 682.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 724.00 Cr.. The value appears strong and on an upward trend. It has increased from 713.00 Cr. (Mar 2024) to 724.00 Cr., marking an increase of 11.00 Cr..
• For CWIP, as of Mar 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 8.00 Cr., marking an increase of 8.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 4,180.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,516.00 Cr. (Mar 2024) to 4,180.00 Cr., marking an increase of 664.00 Cr..
• For Total Assets, as of Mar 2025, the value is 4,911.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,229.00 Cr. (Mar 2024) to 4,911.00 Cr., marking an increase of 682.00 Cr..

Notably, the Reserves (4,172.00 Cr.) exceed the Borrowings (41.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Pfizer Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 136.46. This value is within the healthy range. It has increased from 120.51 (Mar 24) to 136.46, marking an increase of 15.95.
• For Diluted EPS (Rs.), as of Mar 25, the value is 167.79. This value is within the healthy range. It has increased from 120.51 (Mar 24) to 167.79, marking an increase of 47.28.
• For Cash EPS (Rs.), as of Mar 25, the value is 181.07. This value is within the healthy range. It has increased from 134.12 (Mar 24) to 181.07, marking an increase of 46.95.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 921.84. It has increased from 785.91 (Mar 24) to 921.84, marking an increase of 135.93.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 921.84. It has increased from 785.91 (Mar 24) to 921.84, marking an increase of 135.93.
• For Dividend / Share (Rs.), as of Mar 25, the value is 165.00. This value exceeds the healthy maximum of 3. It has increased from 35.00 (Mar 24) to 165.00, marking an increase of 130.00.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 498.65. It has increased from 479.38 (Mar 24) to 498.65, marking an increase of 19.27.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 199.45. This value is within the healthy range. It has increased from 178.32 (Mar 24) to 199.45, marking an increase of 21.13.
• For PBIT / Share (Rs.), as of Mar 25, the value is 186.16. This value is within the healthy range. It has increased from 164.71 (Mar 24) to 186.16, marking an increase of 21.45.
• For PBT / Share (Rs.), as of Mar 25, the value is 222.10. This value is within the healthy range. It has increased from 163.07 (Mar 24) to 222.10, marking an increase of 59.03.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 167.78. This value is within the healthy range. It has increased from 120.51 (Mar 24) to 167.78, marking an increase of 47.27.
• For PBDIT Margin (%), as of Mar 25, the value is 39.99. This value is within the healthy range. It has increased from 37.19 (Mar 24) to 39.99, marking an increase of 2.80.
• For PBIT Margin (%), as of Mar 25, the value is 37.33. This value exceeds the healthy maximum of 20. It has increased from 34.35 (Mar 24) to 37.33, marking an increase of 2.98.
• For PBT Margin (%), as of Mar 25, the value is 44.53. This value is within the healthy range. It has increased from 34.01 (Mar 24) to 44.53, marking an increase of 10.52.
• For Net Profit Margin (%), as of Mar 25, the value is 33.64. This value exceeds the healthy maximum of 10. It has increased from 25.13 (Mar 24) to 33.64, marking an increase of 8.51.
• For Return on Networth / Equity (%), as of Mar 25, the value is 18.20. This value is within the healthy range. It has increased from 15.33 (Mar 24) to 18.20, marking an increase of 2.87.
• For Return on Capital Employeed (%), as of Mar 25, the value is 19.61. This value is within the healthy range. It has decreased from 20.46 (Mar 24) to 19.61, marking a decrease of 0.85.
• For Return On Assets (%), as of Mar 25, the value is 15.62. This value is within the healthy range. It has increased from 13.03 (Mar 24) to 15.62, marking an increase of 2.59.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.49. It has decreased from 0.53 (Mar 24) to 0.49, marking a decrease of 0.04.
• For Current Ratio (X), as of Mar 25, the value is 6.17. This value exceeds the healthy maximum of 3. It has increased from 5.07 (Mar 24) to 6.17, marking an increase of 1.10.
• For Quick Ratio (X), as of Mar 25, the value is 5.33. This value exceeds the healthy maximum of 2. It has increased from 4.27 (Mar 24) to 5.33, marking an increase of 1.06.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 4. It has decreased from 0.78 (Mar 24) to 0.59, marking a decrease of 0.19.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 20.86. This value is within the healthy range. It has decreased from 33.19 (Mar 24) to 20.86, marking a decrease of 12.33.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 19.33. This value is below the healthy minimum of 20. It has decreased from 29.82 (Mar 24) to 19.33, marking a decrease of 10.49.
• For Earning Retention Ratio (%), as of Mar 25, the value is 79.14. This value exceeds the healthy maximum of 70. It has increased from 66.81 (Mar 24) to 79.14, marking an increase of 12.33.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 80.67. This value exceeds the healthy maximum of 70. It has increased from 70.18 (Mar 24) to 80.67, marking an increase of 10.49.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 108.50. This value is within the healthy range. It has increased from 52.94 (Mar 24) to 108.50, marking an increase of 55.56.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 71.72. This value is within the healthy range. It has increased from 36.26 (Mar 24) to 71.72, marking an increase of 35.46.
• For Enterprise Value (Cr.), as of Mar 25, the value is 15,519.59. It has decreased from 17,140.82 (Mar 24) to 15,519.59, marking a decrease of 1,621.23.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.80. This value exceeds the healthy maximum of 3. It has decreased from 7.82 (Mar 24) to 6.80, marking a decrease of 1.02.
• For EV / EBITDA (X), as of Mar 25, the value is 17.01. This value exceeds the healthy maximum of 15. It has decreased from 21.01 (Mar 24) to 17.01, marking a decrease of 4.00.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.03. This value exceeds the healthy maximum of 3. It has decreased from 8.75 (Mar 24) to 8.03, marking a decrease of 0.72.
• For Retention Ratios (%), as of Mar 25, the value is 79.13. This value exceeds the healthy maximum of 70. It has increased from 66.80 (Mar 24) to 79.13, marking an increase of 12.33.
• For Price / BV (X), as of Mar 25, the value is 4.34. This value exceeds the healthy maximum of 3. It has decreased from 5.34 (Mar 24) to 4.34, marking a decrease of 1.00.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.03. This value exceeds the healthy maximum of 3. It has decreased from 8.75 (Mar 24) to 8.03, marking a decrease of 0.72.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.04, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness